<DOC>
	<DOCNO>NCT02124083</DOCNO>
	<brief_summary>Niemann-Pick disease type C ( NPC ) lethal , autosomal recessive , lysosomal storage disorder characterize neurodegeneration early childhood death adolescence . The causative gene NPC1 ( 95 % case ) NPC2 ( 5 % case ) involve intracellular trafficking lipid cholesterol . Mutations either gene lead progressive accumulation unesterified cholesterol lipid central nervous system ( CNS ) . Vorinostat histone deacetylase inhibitor show vivo increase mutant NPC1 protein level reverse cellular accumulation unesterified cholesterol . Vorinostat label FDA treatment cutaneous T-cell lymphoma . In Phase I , non-randomized , open-label , single-center study , plan study whether Vorinostat repurposed treat patient NPC1 . Our primary objective determine safety tolerability Vorinostat NPC1 disease . Our secondary objective determine biochemical efficacy Vorinostat increase expression NPC1 protein normalize lipid protein biomarkers . This study enroll 12 NPC1 patient test safety two dose level ( 200 400 mg ) . Drug administer 3 day on/4 day schedule 3 month dose level . Patients evaluate NIH Clinical Center 0 , 3 6 month . Safety assess adverse event ( AEs ) , clinical laboratory test physical examination . Biochemical efficacy assess measurement serum cerebral spinal fluid biomarkers . Clinical efficacy evaluate audiologic testing , assessment ataxia , swallow study .</brief_summary>
	<brief_title>Phase 1/2 Study Vorinostat Therapy Niemann-Pick Disease , Type C1</brief_title>
	<detailed_description>Niemann-Pick disease type C ( NPC ) lethal , autosomal recessive , lysosomal storage disorder characterize neurodegeneration early childhood death adolescence . The causative gene NPC1 ( 95 % case ) NPC2 ( 5 % case ) involve intracellular trafficking lipid cholesterol . Mutations either gene lead progressive accumulation unesterified cholesterol lipid central nervous system ( CNS ) . Vorinostat histone deacetylase inhibitor show vivo increase mutant NPC1 protein level reverse cellular accumulation unesterified cholesterol . Vorinostat label FDA treatment cutaneous T-cell lymphoma . In Phase I , non-randomized , open-label , single-center study , plan study whether Vorinostat repurposed treat patient NPC1 . Our primary objective determine safety tolerability Vorinostat NPC1 disease . Our secondary objective determine biochemical efficacy Vorinostat increase expression NPC1 protein normalize lipid protein biomarkers . This study enroll 12 NPC1 patient test safety two dose level ( 200 400 mg ) . Drug administer 3 day on/4 day schedule 3 month dose level . Patients evaluate NIH Clinical Center 0 , 3 6 month . Safety assess adverse event ( AEs ) , clinical laboratory test physical examination . Biochemical efficacy assess measurement serum cerebral spinal fluid biomarkers . Clinical efficacy evaluate audiologic testing , assessment ataxia , swallow study .</detailed_description>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Aged great equal 18 less equal 60 year old time enrollment , either gender , ethnicity . 2 . Diagnosis NPC1 base upon one follow : Two NPC1 mutation ; Positive filipin stain least one NPC1 mutation ; Vertical supranuclear gaze palsy ( VSNGP ) combination either : One NPC1 mutation , Positive filipin stain pathogenic NPC2 mutation . 3 . Patients least one neurological manifestation NPC1 . For example , limit , hear loss , vertical supranuclear gaze palsy , ataxia , dementia , dystonia , seizure , dysarthria , dysphagia . 4 . A patient culture skin fibroblast treat 10 M Vorinostat must exhibit reduction filipin lysosomal storage organelle ratio equivalent 75 % response measure NPC1 positive control fibroblast . 5 . Ability travel NIH Clinical Center repeatedly evaluation followup . 6 . If take miglustat , patient must take constant dose medication less three month prior baseline evaluation must willing maintain dose level duration trial . 7 . Willing discontinue nonprescription supplement , exception ageappropriate multivitamin . 8 . Women reproductive age must willing use effective method contraception duration trial . 9 . Willing participate aspect trial design include serial blood CSF collection . EXCLUSION CRITERIA : 1 . Aged 18 60 year age enrollment trial . 2 . Severe manifestation NPC1 would interfere patient ability comply requirement protocol . 3 . Neurologically asymptomatic patient . 4 . Patients receive form cyclodextrin HDACi attempt treat NPC1 . 5 . History hypersensitivity reaction Vorinostat component formulation . 6 . Pregnancy breastfeed time study . 7 . Patients suspected infection CNS systemic infection . 8 . Neutropenia , define absolute neutrophil count ( ANC ) less 1,500 per microliter . 9 . Thrombocytopenia define platelet count le 75,000 per microliter , history great equal grade 2 thrombocytopenia ( 50,00075,000 platelets/microliter ) . 10 . Prior use anticoagulant history/presence bleed disorder . 11 . Hepatic laboratory parameter ( aspartate aminotransferase ( AST ) , alanine aminotransferase , ( ALT ) ) great fourtimes upper limit normal . 12 . Presence anemia define two standard deviation normal age gender . 13 . Serum creatinine level great 1.5 time upper limit normal . 14 . Hematuria ( great than15 RBC/mcL positive hemoglobin ) . This exclusion criterion apply female currently menstruate history renal disease evidence renal impairment ( eg hypertension , serum creatinine upper limit normal , history renal disease ) . Urinalyis repeat menses end drug discontinue hematuria persists . Efforts make avoid menses schedule initial admission . 15 . Proteinuria ( 1+ protein urinalysis ) Patient exclude urine protein/creatinine ratio normal classify benign either patient 's primary medical provider upon obtain nephrology consult . 16 . Serum potassium Magnesium outside normal laboratory range prior initiation vorinostat therapy . 17 . Diabetes fast glucose great 106 mg/dl . 18 . Active pulmonary disease , oxygen requirement clinically significant history decrease blood oxygen saturation , pulmonary therapy , require active suction . 19 . Patients uncontrolled seizure per either criterion . 1 . Unstable frequency , type duration seizure . Quantified seizure log two month prior enrollment . 2 . Patients require antiepileptic medication change ( dose adjustment weight ) two month prior enrollment , require three antiepileptic medication control seizures . 20 . Use another HDAC inhibitor compound establish HDAC inhibitory activity , include valproic acid , unless discontinue least 2 month prior enrollment . 21 . History thromboembolic event ( DVT Pulmonary embolism ) . 22 . Patients , opinion investigator , unable comply protocol specific health concern would potentially increase risk participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 29, 2017</verification_date>
	<keyword>Niemann Pick Disease , Type C1</keyword>
	<keyword>Phase I , Phase 2</keyword>
	<keyword>Vorinostat</keyword>
</DOC>